The SeriousTraders Newsletter If you are Serious about Trading, become a SeriousTrader!™

Kairos Pharma Ltd. (NYSE American: KAPA)

Investment Considerations Kairos Pharma’s partnership with Cedars-Sinai Medical Center enhances clinical trial efficiency and accelerates the development of new therapeutic solutions. The company holds a robust intellectual property portfolio with patents extending through 2040, providing a strong competitive advantage in the oncology market. ENV105, Kairos’s lead drug candidate, shows promise in reversing drug resistance in … Continue reading “Kairos Pharma Ltd. (NYSE American: KAPA)”

View Profile